紫杉醇联合或不联合曲美替尼或帕唑帕尼治疗晚期野生型BRAF黑色素瘤(PACMEL):一项多中心、开放标签、随机对照II期试验
加用曲美替尼显著改善6个月PFS(时间比1.47,90%CI 1.08-2.01,P=0.04)和客观缓解率(42% vs 13%,P=0.01),但未影响总生存期(P=0.25);加用帕唑帕尼未改善6个月PFS、客观缓解率或总生存期。两种联合方案毒性均增加。
要点
- 加用曲美替尼显著改善6个月PFS(时间比1.47,90%CI 1.08-2.01,P=0.04)和客观缓解率(42% vs 13%,P=0.01)。
- 加用曲美替尼未影响总生存期(P=0.25)。
- 加用帕唑帕尼未改善6个月PFS(时间比1.36,90%CI 0.96-1.93,P=0.14)、客观缓解率或总生存期。
核心结论
- 在这项II期试验中,对野生型BRAF黑色素瘤患者在紫杉醇化疗基础上加用曲美替尼改善了PFS并大幅提高客观缓解率,但未影响总生存期。
研究设计与样本
- 多中心、开放标签、随机对照II期试验,按1:1:1随机分配至紫杉醇单药组(n=38)、紫杉醇联合曲美替尼组(n=36)或紫杉醇联合帕唑帕尼组(n=37)。
- 紫杉醇最多给药6个周期,曲美替尼2 mg和帕唑帕尼800 mg口服每日一次,直至疾病进展或不可接受的毒性。
- 参与者和研究者均未设盲,主要终点为无进展生存期(PFS)。
主要发现
- 加用曲美替尼显著改善6个月PFS(时间比1.47,90%CI 1.08-2.01,P=0.04)和客观缓解率(42% vs 13%,P=0.01),但未影响总生存期(P=0.25)。
- 加用帕唑帕尼未改善6个月PFS(时间比1.36,90%CI 0.96-1.93,P=0.14)、客观缓解率或总生存期。
- 两种联合方案毒性均增加。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Advanced melanoma treatments often rely on immunotherapy or targeting mutations, with few treatment options for wild-type BRAF (BRAF-wt) melanoma. However, the mitogen-activated protein kinase pathway is activated in most melanoma, including BRAF-wt. We assessed whether inhibiting this pathway by adding kinase inhibitors trametinib or pazopanib to paclitaxel chemotherapy improved outcomes in patients with advanced BRAF-wt melanoma in a phase II, randomised and open-label trial. PATIENTS AND METHODS: Patients were randomised (1 : 1 : 1) to paclitaxel alone or with trametinib or pazopanib. Paclitaxel was given for a maximum of six cycles, while 2 mg trametinib and 800 mg pazopanib were administered orally once daily until disease progression or unacceptable toxicity. Participants and investigators were unblinded. The primary end point was progression-free survival (PFS). Key secondary end points included overall survival (OS) and objective response rate (ORR). RESULTS: Participants were randomised to paclitaxel alone (n = 38), paclitaxel and trametinib (n = 36), or paclitaxel and pazopanib (n = 37). Adding trametinib significantly improved 6-month PFS [time ratio (TR), 1.47; 90% confidence interval (CI) 1.08-2.01, P = 0.04] and ORR (42% versus 13%; P = 0.01) but had no effect on OS (P = 0.25). Adding pazopanib did not benefit 6-month PFS; (TR 1.36; 90% CI 0.96-1.93; P = 0.14), ORR, or OS. Toxicity increased in both combination arms. CONCLUSION: In this phase II trial, adding trametinib to paclitaxel chemotherapy for BRAF-wt melanoma improved PFS and substantially increased ORR but did not impact OS.This study was registered with the EU Clinical Trials Register, EudraCT number 2011-002545-35, and with the ISRCTN registry, number 43327231.
引用
- Urbonas V, Schadendorf D, Zimmer L, et al. Paclitaxel with or without trametinib or pazopanib in advanced wild-type BRAF melanoma (PACMEL): a multicentre, open-label, randomised, controlled phase II trial. Ann Oncol. 2019. PMID: 30428063. doi:10.1093/annonc/mdy500
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。